Guangxiu Dai
Zhangjiang Hi Tech Park
Zhangjiang, China
Zhangjiang, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment.
Journal: ACS medicinal chemistry letters
Published: December 25, 2024
Preclinical pharmacokinetic characterization of amdizalisib, a novel PI3Kδ inhibitor for the treatment of hematological malignancies.
Journal: Frontiers in pharmacology
Published: February 27, 2024
Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.
Journal: ACS medicinal chemistry letters
Published: December 06, 2023
Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor.
Journal: The Journal of pharmacology and experimental therapeutics
Published: May 21, 2023
Phase I study of the Syk inhibitor sovleplenib in relapsed or refractory mature B-cell tumors.
Journal: Haematologica
Published: November 09, 2022
Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.
Journal: Pharmacology research & perspectives
Published: December 08, 2019
Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
Journal: Journal of medicinal chemistry
Published: April 30, 2019
Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
Journal: Journal of medicinal chemistry
Published: August 23, 2014
Showing 1-8 of 8
Last Updated: 09/26/2026